1 Department of Molecular Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto University, Japan.
2 Department of Applied Pharmaceutics and Pharmacokinetics, Graduate School of Pharmaceutical Sciences, Kyoto University, Japan.
Mol Pain. 2018 Jan-Dec;14:1744806918789812. doi: 10.1177/1744806918789812. Epub 2018 Jul 3.
Background Diabetic peripheral neuropathy is a common long-term complication of diabetes. Accumulating evidence suggests that vascular impairment plays important roles in the pathogenesis of diabetic peripheral neuropathy, while the mechanism remains unclear. We recently reported that transient receptor potential ankyrin 1 (TRPA1) is sensitized by hypoxia, which can contribute to cold hypersensitivity. In this study, we investigated the involvement of TRPA1 and vascular impairment in painful diabetic peripheral neuropathy using streptozotocin-induced diabetic model mice. Results Streptozotocin-induced diabetic model mice showed mechanical and cold hypersensitivity with a peak at two weeks after the streptozotocin administration, which were likely to be paralleled with the decrease in the skin blood flow of the hindpaw. Streptozotocin-induced cold hypersensitivity was significantly inhibited by an antagonist HC-030031 (100 mg/kg) or deficiency for TRPA1, whereas mechanical hypersensitivity was unaltered. Consistent with these results, the nocifensive behaviors evoked by an intraplantar injection of the TRPA1 agonist allyl isothiocyanate (AITC) were enhanced two weeks after the streptozotocin administration. Both streptozotocin-induced cold hypersensitivity and the enhanced AITC-evoked nocifensive behaviors were significantly inhibited by a vasodilator, tadalafil (10 mg/kg), with recovery of the decreased skin blood flow. Similarly, in a mouse model of hindlimb ischemia induced by the ligation of the external iliac artery, AITC-evoked nocifensive behaviors were significantly enhanced three and seven days after the ischemic operation, whereas mechanical hypersensitivity was unaltered in TRPA1-knockout mice. However, no difference was observed between wild-type and TRPA1-knockout mice in the hyposensitivity for current or mechanical stimulation or the deceased density of intraepidermal nerve fibers eight weeks after the streptozotocin administration. Conclusion These results suggest that TRPA1 sensitization during diabetic vascular impairment causes cold, but not mechanical, hypersensitivity in the early painful phase of diabetic peripheral neuropathy. However, TRPA1 may play little or no role in the progression of diabetic peripheral neuropathy.
糖尿病周围神经病变是糖尿病的一种常见长期并发症。越来越多的证据表明,血管损伤在糖尿病周围神经病变的发病机制中起重要作用,但其机制尚不清楚。我们最近报道,瞬时受体电位锚蛋白 1(TRPA1)在缺氧时被敏化,这可能导致对冷的超敏反应。在这项研究中,我们使用链脲佐菌素诱导的糖尿病模型小鼠研究了 TRPA1 和血管损伤在痛性糖尿病周围神经病变中的作用。
链脲佐菌素诱导的糖尿病模型小鼠表现出机械和冷超敏反应,在链脲佐菌素给药后两周达到峰值,这可能与后足皮肤血流量的减少相平行。TRPA1 拮抗剂 HC-030031(100mg/kg)或 TRPA1 缺陷显著抑制链脲佐菌素引起的冷超敏反应,而机械超敏反应无变化。与这些结果一致的是,在链脲佐菌素给药两周后,足底注射 TRPA1 激动剂丙烯基异硫氰酸酯(AITC)引起的伤害性行为增加。血管扩张剂他达拉非(10mg/kg)显著抑制链脲佐菌素引起的冷超敏反应和增强的 AITC 诱导的伤害性行为,并恢复降低的皮肤血流量。同样,在股外侧动脉结扎引起的小鼠后肢缺血模型中,AITC 诱导的伤害性行为在缺血术后 3 天和 7 天明显增强,而在 TRPA1 敲除小鼠中机械超敏反应无变化。然而,在链脲佐菌素给药 8 周后,野生型和 TRPA1 敲除小鼠在电流或机械刺激的低敏性以及表皮内神经纤维密度的降低方面没有差异。
这些结果表明,糖尿病血管损伤期间的 TRPA1 敏化导致糖尿病周围神经病变早期痛性阶段的冷,但不是机械性超敏反应。然而,TRPA1 可能在糖尿病周围神经病变的进展中作用不大或没有作用。